Medivir AB (LTS:0GP7) Receivables Turnover : 0.10 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Medivir AB Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Medivir AB's Revenue for the three months ended in Mar. 2024 was kr0.50 Mil. Medivir AB's average Accounts Receivable for the three months ended in Mar. 2024 was kr5.00 Mil. Hence, Medivir AB's Receivables Turnover for the three months ended in Mar. 2024 was 0.10.

Medivir AB Receivables Turnover Historical Data

The historical data trend for Medivir AB's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Receivables Turnover Chart

Medivir AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

78.24

357.64

1,702.47

Medivir AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial															0.08	0.34	0.13	0.79	0.10

Competitive Comparison of Medivir AB's Receivables Turnover

For the Biotechnology subindustry, Medivir AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medivir AB's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Medivir AB's Receivables Turnover falls into.

Medivir AB Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Medivir AB's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	7.634	/ (	(0	+	0)	/	1 )
=	7.634	/	0
=	N/A

Medivir AB's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	0.5	/ (	(0	+	5)	/	1 )
=	0.5	/	5
=	0.10

Medivir AB (LTS:0GP7) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Medivir AB Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Medivir AB's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (LTS:0GP7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (LTS:0GP7) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.

Medivir AB (LTS:0GP7) Headlines

No Headlines